Healthcare entity

Cibotercept

Product

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.

Last mentioned: Mar 4, 2026

Entity pulse

Recent coverage · Cibotercept

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Cibotercept

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. Cibotercept appears in 1 tracked Healthcare story from March 4, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Cibotercept. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. FY 2025 Earnings

    Released full-year financial results and updated 2026 clinical guidance.

  2. Anticipated Data

    Expected top-line data readouts for multiple Phase 2 programs.

  3. Cibotercept Progress

    Initiated additional cohorts in PAH studies to evaluate dose-response.

  4. Trial Expansion

    Keros expanded the TROPOS trial to include broader MDS patient populations.

Stories mentioning Cibotercept 1

Cibotercept is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.